Ciclesonide

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Ciclesonide
Ciclesonide.svg
Ciclesonide ball-and-stick from crystal.png
Clinical data
Synonyms (11β, 16α)-16, 17-[[(R)-cyclohexylmethylene]bis(oxy)]-11-hydroxy-21- (2-methyl-1-oxopropoxy)- pregna-1, 4-diene-3, 20-dione
AHFS/Drugs.com Monograph
MedlinePlus a607008
Pregnancy
category
  • AU: B3
  • US: C (Risk not ruled out)
Routes of
administration
Nasal inhalation
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C32H44O7
Molar mass 540.688 g/mol
3D model (JSmol)
 NYesY (what is this?)  (verify)

Ciclesonide is a glucocorticoid used to treat asthma and allergic rhinitis. It is marketed under the brand names Alvesco for asthma and Omnaris, Omniair, and Zetonna for hay fever in the US and Canada. Phase 3 trials for the hay fever indication outside the US are ongoing.[1] The drug was approved for adults and children 12 and over by the US Food and Drug Administration in October 2006.[2] Side effects of the medication include headache, nosebleeds, and inflammation of the nose and throat linings.[3]

See also[edit]

References[edit]

  1. ^ "OMNARIS/OMNAIR". Products. Nycomed International Management GmbH. 2009. Archived from the original on February 2, 2009. Retrieved 2009-07-30. 
  2. ^ "FDA NEWS RELEASE. FDA Approves New Treatment for Allergies". Food and Drug Administration. 2006-10-23. Retrieved 2009-07-30. 
  3. ^ Mutch, Elaine; Nave, Ruediger; McCracken, Nigel; Zech, Karl; Williams, Faith M. (2007). "The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue". Biochemical Pharmacology. 73 (10): 1657–64. doi:10.1016/j.bcp.2007.01.031. PMID 17331475. 

Further reading[edit]

  • Rossi S (Ed.) (2006). Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook. ISBN 0-9757919-2-3